| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0007 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.093 | 0.004 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.004 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.088 | 0.006 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.13 | 0.008 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.009 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.01 |